Government ContextGovernment Context
ActivityRulesGrantsPress releasesHearingsBills
ViewsAgenciesTopicsOrganizationsCommitteesLegislators
PricingLog inCreate account
Nonrulemaking

Requests that the FDA declare that Cyproheptadine Hydrochloride Orally Disintegrating Tablets, 2 mg, 3 mg, 4 mg and 6 mg is suitable for submission as an ANDA.

🏛 Food and Drug Administration (FDA)FDA-2026-P-6811
Pharmaceutical Policy
Documents
6
Total comments
0
all analyzed
Comment status
Open
Last activity
—
In this docket

Documents

Rules, notices, and supporting material — the primary rule pinned first.

All 6Other 3Supporting & Related Material 3
📄 Primary document
OtherJun 25, 2026
Completeness Assessment Correspondence to Senores Pharmaceuticals, Inc.
No comment period
Open →